Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation | Modakafusp alfa (TAK-573) | Relapsed/Refractory Multiple Myeloma | Phase 3 | Trial Planned | Intravenous | Oncology |
| Adaptive Biotechnologies Corporation | Abecma (idecabtagene vicleucel) - (KarMMa-9) | Newly Diagnosed Multiple Myeloma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| ADC Therapeutics SA | Camidanlumab tesirine - (Cami) | Hodgkin lymphoma (HL) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| ADC Therapeutics SA | ZYNLONTA (loncastuximab tesirine-lpyl) | Relapsed/refractory (r/r) marginal zone lymphoma (MZL) | Phase 2 | Data Released | Intravenous | Oncology |
| ADC Therapeutics SA | ZYNLONTA (Loncastuximab Tesirine) and RITUXAN (rituximab) - (LOTIS-5) | Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Ongoing | Intravenous | Oncology |
| ADC Therapeutics SA | ZYNLONTA (loncastuximab tesirine-lpyl) with rituximab (Lonca-R) - (LOTIS-9) | High-Risk Relapsed/Refractory Follicular Lymphoma | Phase 2 | Data Released | Intravenous | Oncology |
| ADC Therapeutics SA | Loncastuximab tesirine - (LOTIS-2) | Diffuse Large B-Cell Lymphoma | Phase 2 | Data Released | Intravenous | Oncology |
| ADC Therapeutics SA | ZYNLONTA (loncastuximab tesirine) + IMBRUVICA (Ibrutinib) - (LOTIS-3) | Diffuse Large B-Cell (DLBCL) or Mantle Cell Lymphoma (MCL) | Phase 2 | Trial Discontinued | Intravenous Oral | Oncology |
